The FDA has approved Fabhalta (iptacopan) for the treatment of adults with complement 3 glomerulopathy (C3G), to reduce proteinuria.

A research team has developed a compact peritoneal dialysis device that can be utilized as a portable artificial kidney. This ...

Professor Kenji Osafune (Department of Cell Growth and Differentiation) and his team of researchers have devised an effective ...

For patients with polycystic kidney disease (PKD), a common genetic disorder that ravages the waste-removing organ with cysts ...

Novartis ( NYSE: NVS) said on Thursday that it received US FDA's accelerated approval for Vanrafia as a treatment for adults ...

For patients with polycystic kidney disease (PKD), a common genetic disorder that ravages the waste-removing organ with cysts ...

Microwave ablation is an effective treatment modality for T1a and selected T1b renal cell carcinoma (RCC). Independent of the ...

Apellis Pharmaceuticals APLS announced that the FDA has accepted its supplemental new drug application (sNDA) seeking the ...

Excess weight in mid-life is a known risk factor for kidney cancer, but new research indicates that weight patterns throughout life may also affect an individual’s likelihood of developing this ...

There were a number of notable developments for patients with kidney cancer at the symposium, Dr. Emre Yekedüz explained.

These findings emphasize that maintaining a healthy weight across one’s lifetime is important for reducing RCC risk, the researchers stated.

“Maintaining a healthy weight across one’s lifetime” can prevent the development of kidney cancer, a new study has indicated. In the trial, the team of researchers looked at the weight patterns of 204 ...